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Edited by Jesus AvilaAbstract Markers of oxidative stress in peripheral blood from
patients with Alzheimer disease (AD) were analyzed. Thirty-
three AD patients were recruited. Plasma antioxidant power
(AOP), plasma Cystatin C as well as Cathepsin D in PBL were
evaluated. We found that the AOP levels were signiﬁcantly de-
creased in AD patients if compared to healthy donors, while
the plasma level of Cystatin C was signiﬁcantly higher. Impor-
tantly, a signiﬁcantly decreased expression of Cathepsin D in
PBL was also observed. These results suggest that oxidative
imbalance in the peripheral blood of AD patients could mirror
oxidative changes previously described in the central nervous
system.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Oxidative stress, resulting in excessive production of reactive
oxygen species (ROS), is related to a variety of neuronal disor-
ders caused by cerebrovascular injury, neuropathology and
aging. One theory on the pathogenesis of Alzheimers disease
(AD) postulates that neurodegeneration is the result of oxida-
tive stress and damage to vulnerable cerebral tissues [31]. The
oxidative stress hypothesis in AD has been further strength-
ened by demonstration of (i) increased levels of trace elementsAbbreviations: AD, Alzheimer disease; a-Fas, anti-human Fas IgM
monoclonal antibody; AOP, plasma antioxidant power; APP, amyloid
precursor protein A4; CRAOP, Cu+-reducing antioxidant power; CT,
cranial tomography; FT, fronto-temporal dementia; HD, healthy do-
nors; IL-2, interleukin 2; IVM, intensiﬁed video microscopy; MCI,
mild cognitive impairment; MMSE, mini mental state examination;
MRI, magnetic resonance imaging; NAP, non-Alzheimer patients;
PBL, peripheral blood lymphocytes; PD, Parkinson disease; PHA,
phytohemoagglutinin; ROS, reactive oxygen species; SE, standard
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doi:10.1016/j.febslet.2005.03.094such as iron, mercury and aluminum, which are potent cata-
lysts for free radical generation in the brain of AD patients
and (ii) beneﬁcial eﬀects of antioxidant treatment with a-
tocopherol or selegiline in AD patients [14].
Signs of oxidative stress in AD are concomitant with b-amy-
loid deposition. This is a metalloprotein electrochemically ac-
tive that binds copper and converts molecular oxygen into
hydrogen peroxide by reducing copper or iron leading to
Fenton chemistry. Hydrogen peroxide is a freely permeable
pro-oxidant that may be responsible for many of the oxidative
adducts that form in the Alzheimer-aﬀected brain [26]. More-
over, in some neuropathological studies, markers of protein
oxidation, DNA (mainly mitochondrial) oxidation and lipid
peroxidation have been described, suggesting the occurrence
of an oxidative stress in AD [9]. However, the co-occurrence
of a systemic oxidative stress with brain oxidative stress during
AD remains hypothetical. A major limitation in assessing sys-
temic oxidative stress by examining markers in the peripheral
circulation is that it gives a global assessment, with no indication
as to the actual site of the oxidative stress. A confounding factor
in the systemic oxidative stress evaluation is that aging itself
seems to be associatedwith increased oxidative imbalance [2,43].
The aim of this work was to compare the oxidative stress
markers in plasma, peripheral blood lymphocytes (PBL) and
platelets from AD patients with age matched control subjects,
in order to evaluate if the oxidative stress was not restricted to
the brain but could also be recognized in the peripheral circu-
lation. The following parameters were considered: (i) plasmatic
antioxidant power (AOP), by evaluating Cu++ reduction on
behalf of all present antioxidants, and (ii) plasma concentra-
tion of Cystatin C, a cathepsin inhibitor that was found to
be co-localized with b-amyloid peptide [48]. Moreover, periph-
eral lymphocytes and platelets were also considered. In partic-
ular, (iii) concentration of Cathepsin D, an aspartyl protease,
in PBL and (iv) the concentration of amyloid precursor protein
A4 (APP) in platelets and PBL were evaluated.2. Materials and methods
2.1. Subjects
We recruited 33 patients with Alzheimer disease (AD) according to
the NINCDS-ADRDA criteria [32] and 33 healthy donors (HD)
from the Day Hospital of the Department of Geriatrics, Gerontology
and Physiatry of the Catholic University of Rome (Italy). Clinical clas-
siﬁcation of AD was determined according to the Diagnostic andblished by Elsevier B.V. All rights reserved.
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Neurological and Communicative Disorders and Stroke-Alzheimers
Disease and Related Disorders Association criteria [38]. Healthy do-
nors were recruited from subjects who underwent a day-hospital med-
ical screening in order to follow a ﬁtness program. A low number of
additional patients (n = 10) displaying prodromal symptoms of demen-
tia (apathy, disinhibition, irritability and aggressiveness) were also con-
sidered. These were diagnosed as patients with Parkinson Disease (PD,
4 patients), Frontotemporal dementia (2 patients), following the guide-
lines designed elsewhere McKhann et al. [33] or a neurodegenerative
disorder characterized by initial symptoms resembling those of AD,
i.e. mild cognitive impairment (MCI, diagnosed after a follow-up of
at least 2.0 years, 4 patients). These patients were indicated as non-Alz-
heimer patients (NAP).
All AD, HD and NAP groups were matched for age and sex. A com-
prehensive physical examination, laboratory blood testing were under-
taken for all subjects; CT scan or MRI were carried out in AD and
NAP. No subject from the three groups was suﬀering from neurolog-
ical or major medical diseases, including diabetes, except for moderate
increment of blood pressure (140 ± 10/80 ± 5 mmHg) or serum choles-
terol (200 ± 20 mg/100 ml). No subject was malnourished or had med-
ical history positive for psychiatric disorders, drug or alcohol abuse or
brain injury. All AD patients received stable doses of cholinesterase
inhibitors. All patients and normal donors had laboratory analysis
of serum albumin, cholesterol, platelets and total level of Cu. No sig-
niﬁcant diﬀerence was however found among the diﬀerent groups for
what concerns laboratory parameters (see Table 1).
The nature and purpose of study was explained to all participants.
The ethical committee of the Catholic University proved the study.
2.2. Sample collection
The sampling protocol was designed to minimize oxidation after col-
lection. Venous blood (20 ml) was collected from subjects in heparin-
ized tubes, maintained at room temperature throughout preparation.
2.2.1. Plasma samples. For plasma isolation, blood was centrifuged
at 3000 · g for 10 min at room temperature. Plasma was removed, ali-
quoted and frozen until analyses.
2.2.2. Platelet isolation. Platelet-rich plasma was prepared by cen-
trifugation of whole blood at 100 · g for 15 min at room temperature.
The platelet-rich plasma supernatant was carefully removed and was
used to isolate platelets by stepwise centrifugation as previously de-
scribed [39].
2.2.3. Peripheral blood lymphocytes isolation. Human PBL from
AD patients, NAP patients and HD were isolated from freshly hepa-
rinized blood through a Ficoll–Hypaque density gradient centrifuga-
tion and washed three times in phosphate-buﬀer saline (PBS), pH 7.4
(Lympholyte-H, Cedarlane Laboratories, Hornby, Ont., Canada).
PBL were subcultured in 25 or 75 cm2 Falcon plastic ﬂasks at a density
of approximately 1 · 106 cells/ml in RPMI 1640 (GIBCO-BRL, Life
Technologies Milan, Italy) containing 15% fetal calf serum (Flow Lab-
oratories, Irvine, Scotland), 1% non-essential aminoacids, 5 mM L-glu-
tamine, penicillin (100 IU/ml) and streptomycin (100 mg/ml) at 37 C
in a humidiﬁed 5% CO2 atmosphere. For apoptosis susceptibility anal-
yses PBL were cultured for 72 h with phytohemoagglutinin (PHA 2 lg/
ml, Boeringher Manneheim, Milan, Italy) and interleukin 2 (IL-2, 60
IU/ml, GIBCO) and than triggered for 48 h with 500 ng/ml of an
anti-human Fas IgM monoclonal antibody (a-Fas, clone CH11, Up-
state Biotechnology, Lake Placid, NY, USA).Table 1
Main private and clinical data of AD patients and healthy donors
AD patients Healthy donors
Male/female 15/18 16/17
Age (years) 77.28 ± 4.06 74.82 ± 5.11
MMS E 19.22 ± 5.10 P 26
Blood pressure (mmHg) 140 ± 10/80 ± 5 130 ± 10/80 ± 5
Total cholesterol (mg/100 ml) 200 ± 20 190 ± 10
LDL cholesterol (mg/dl) 146.17 ± 32.67 130.71 ± 42.19
HDL cholesterol (mg/dl) 54.75 ± 33.81 49.87 ± 15.22
Total Cu (lg/100 ml) 60–160 60–160
Albumin (g/l) 4.02 ± 0.427 4.17 ± 0.78
Platelets (109/l) 235 ± 59.95 233 ± 62.592.3. Biochemical analyses in the blood plasma
2.3.1. Plasma antioxidant power. The evaluation of the plasma
AOP was obtained by measuring the Cu+-reducing antioxidant power
(CRAOP) by means of a speciﬁc spectrophometric test (MED.DIA,
Vercelli, Italy). This method provides a quantitative measurement of
the antioxidant capability of a biological ﬂuid, such as plasma, due
to the non-enzymatic antioxidant system. To this system belong lipo-
soluble (the more important is vitamin E) and water-soluble antioxi-
dants (uric acid, vitamin C, bilirubin, reduced thiols and glutathione).
Since the diﬀerent diet followed by the patients can represent an impor-
tant variable, e.g. for certain antioxidants such as vitamin C, the AOP
was carried out by taking into account the action of the whole antiox-
idants present in the plasma. The antioxidant capability of our samples
was obtained by evaluating Cu+ derived by the reduction of Cu++,
which was added at known concentrations either to standard or to
experimental samples. Cu+ forms a stable complex with bathocupro-
ine, which has a typical absorption to 480–490 nm and it is thus reveal-
able by a spectrophotometer. For these reasons we selected healthy
donors and pathological subjects with comparable amount of plas-
matic Cu (see Table 1). Values detected in experimental samples were
compared with the curve obtained from standard samples at known
concentrations of uric acid used as typical riducent and expressed as
lM [46,50]. To verify the results obtained by CRAOP we also indi-
rectly measured the AOP of plasma by a spectrophotometric assay
as reported by Valkonen and Kuusi [49]. In this assay we used H2O2
as oxidant compound and DCFH-DA as oxidable substrate. The oxi-
dation of DCFH-DA by standard doses of H2O2 (3, 5, 10, 25, 50,
100 lM) converts it to dichloroﬂuorescein (DCF), which is highly ﬂuo-
rescent (Ex 480 nm, Em 526 nm) and also has absorbance at 504 nm.
Following this protocol, the AOP of our plasma samples was nega-
tively correlated with the absorbance values obtained. Importantly, re-
sults obtained by using this method, completely independent from the
level of Cu in the plasma, overlapped those obtained by CRAOP. For
this reason only these latter will be shown herein.
2.3.2. Cystatin C detection. Evaluation of Cystatin C in plasma of
AD patients and HDwas performed with a speciﬁc kit from BioVendor
Laboratory Medicine (Brno, Czech Republic) by using 96 multi-wells.
According to the manufacturer instructions standards and plasma sam-
ples from AD patients and HD were incubated for 2 h in microtitration
wells coated with anti-human Cystatin C antibody. After washings,
anti-human Cystatin C antibody labeled with horseradish peroxidase
(HRP) was added to the wells and incubated for 2 additional hours with
the immobilized antibody-Cystatin C complex. Following washing
step, the remaining HRP-conjugated antibody was allowed to react
with the substrate tetramethylbenzidine. The reaction was stopped by
addition of acidic solution and absorbance of the resulting yellow prod-
uct was measured spectrophotometrically at 450 nm. Standard curve
was constructed by plotting absorbance values versus Cystatin C con-
centrations of the standards. Thus, concentrations of our samples were
determined using this standard curves and reported as ng/ml.
2.4. Analytical cytology
2.4.1. Apoptosis evaluation. Quantitative evaluation of apoptosis
was performed by the double staining with FITC-conjugated annexin
V/propidium iodide (PI) by using apoptosis detection kit (Eppendorf,
Milan, Italy), which allows discrimination between early apoptotic (an-
nexin V single positive), late apoptotic (annexin V/PI double positive)
and necrotic (single PI positive) cells.
2.4.2. Analyses of redox balance in freshly isolated lympho-
cytes. Immediately after isolation from peripheral blood, lympho-
cytes (5 · 105 cells) from AD, NAP and HD were incubated in 495 l
of Hanks balanced salt solution (HBSS, pH 7.4) containing 10 lM
dihydrorhodamine 123 (DHR 123, Molecular Probes) or 1 lM dihy-
droethidium (DHE, Molecular Probes) in polypropylene test tubes
for 15 min at 37 C. DHE is a chemically reduced ethidium derivative.
It is a non-ﬂuorescent membrane-permeable dye that can be oxidized
directly to the red ﬂuorescent ethidium bromide by O2 generated inside
the cells after diﬀerent treatments. DHR 123 is a dye freely diﬀusing
into cells, oxidized primarily by H2O2 in a myeloperoxidase-dependent
reaction to green ﬂuorescence. Intracellular content of reduced thiols
was explored by using 10 lM 5-chloromethyl-2 0,7 0-dichloro-dihydro-
ﬂuoresceindiacetate (CM-H2DCFDA, Molecular Probes). Cells ex-
posed to the GSH depleting drug L-buthionine-[S,R]-sulfoximine
7.5 mM (BSO, Sigma) for 16 h were considered as negative controls.
Samples were then analyzed with a FACScan ﬂow cytometer (Becton
E. Straface et al. / FEBS Letters 579 (2005) 2759–2766 2761Dickinson, Mountain View, CA, USA). The median values of ﬂuores-
cence intensity histograms were used to provide semiquantitative
assessment of reduced thiols content and ROS production.
2.4.3. Quantitative and qualitative protein analyses. PBL and plate-
lets from AD patients and HD were ﬁxed with 4% paraformaldehyde
in PBS for 30 min at room temperature. After washing in the same
buﬀer, cells were permeabilizedwith 0.5%TritonX-100 (SigmaChemical
Co, MO, USA) in PBS for 5 min. (a) For Cathepsin D detection, PBL
were stained with a speciﬁc polyclonal antibody (Calbiochem Co,
Darmstadt, Germany) at 37 C for 30 min and, after washing in
PBS, stained with anti-rabbit IgG FITC-conjugated (Sigma) for
30 min at 37 C. (b) For detection of APP, platelets and PBL were
stained at 37 C for 30 min with mouse anti-Alzheimer precursor pro-
tein A4 (APP) monoclonal antibody (Chemicon International, Inc.
Temecula, CA, USA) recognizing a N-terminal epitope of APP
molecule and, after washing in PBS, stained with an anti-mouse IgG
FITC-conjugated (Sigma) at 37 C for 30 min. (c) For microﬁlaments
detection, platelets were stained with ﬂuorescein-phalloidin (Sigma) at
37 C for 30 min. Finally, after washing, samples (a), (b) and (c) were
mounted with glycerol-PBS (2:1) and observed by intensiﬁed video
microscopy (IVM) with a Nikon Microphot ﬂuorescence microscope
equipped with a CCD camera (Zeiss, Heidelberg, Germany), whilst
samples (a) and (b) were also analyzed with a FACScan ﬂow cytometer
(Becton Dickinson).
2.5. Statistical analyses
Cytoﬂuorimetric comparisons between single patients were con-
ducted by CellQuest Software using the parametric Kolmogorov–Smir-
nov (K/S) test on a population of at least 20 000 cells. Only P values of
less than 0.01 were considered as signiﬁcant. Statistical analyses of the
results obtained by various quantitative analyses (i.e., AOP, Cystatin C,
Cathepsin D and APP) were carried out, where appropriate, by using
Mann–Whitney non-parametric test and regression analyses. All anal-
yses were carried out by using Statview 5.1 (software for Macintosh).Fig. 1. Spectrophotometric evaluation of plasmatic antioxidant power
(AOP) and Cystatin C levels. In AD patients it was possible to observe
a highly signiﬁcant decrease (P = 0.0197) of plasmatic antioxidants
with respect to HD (A). Conversely, a signiﬁcant increase of plasmatic
Cystatin C levels was found in plasma from AD patients with respect
to HD (P = 0.0487) (B). Median values ± S.E. are reported.3. Results
3.1. Decreased antioxidant and increased Cystatin C in plasma
from AD patients
We ﬁrst evaluated intracellular redox balance in lymphocytes
and plasma AOP both in AD patients and age-matched HD.
Semiquantitative ﬂow cytometry analysis did not reveal any
signiﬁcant diﬀerence between AD and HD groups as regards
hydhrogen peroxide production (median values of ﬂuorescence
intensity histograms 199 ± 34.3 and 204 ± 30.1, respectively)
and superoxide anion production (median values of ﬂuores-
cence intensity histograms 121 ± 9.6 and 116 ± 10.1, respec-
tively). By contrast, the analysis of plasma AOP evaluated by
CRAOP revealed some important diﬀerence between AD and
HD samples. AOP evaluation was obtained by measuring the
levels of Cu+ derived by reduction from Cu++ due to the action
of all antioxidants (vitamin E, uric acid, vitamin C, bilirubin,
thiols and glutathione) present in the human plasma. What
we found was a signiﬁcant reduction of the AOP in ADwith re-
spect to control blood samples (P = 0.0197). In particular, as
showed in Fig. 1A, a mean reduction of about 52% of AOP
was observed in AD patients with respect to HD. Comparable
results (not shown) were obtained by using the DCFH-DA
spectrophotometric assay (see Section 2). Moreover, Cystatin
C plasma levels, evaluated in the same samples, were signiﬁ-
cantly higher in AD patients with respect to HD (P = 0.0487,
Fig. 1B). Cystatin C is a speciﬁc inhibitor of cathepsins, a fam-
ily of lysosomal proteases, that co-localizes with b-amyloid
peptide and was found increased in cultured neurons exposed
to oxidative stress [35]. Importantly, we observed a strict corre-
lation between AOP and Cystatin C amount as demonstrated
by regression analysis (R = 0.752; P = 0.0048).3.2. Decreased expression of Cathepsin D in lymphocytes from
AD patients
In order to investigate whether the increased levels of plas-
matic Cystatin C was related to the changes occurring in the
expression of its target molecules [23], i.e. cathepsins, a quan-
titative analysis of the lymphocyte-speciﬁc cathepsin, Cathep-
sin D, was conducted in PBL. The median value of
ﬂuorescence intensity histogram of a population of at least
20 000 cells was considered as Cathepsin D expression index
[27]. Results obtained by ﬂow cytometry analyses clearly indi-
cated an alteration in the expression of this molecule. In Fig.
2A, the distribution of the detected values in AD patients and
HD is reported. To note that values obtained appeared diﬀer-
ently scattered in HD with respect to AD samples. In partic-
ular, as shown in Fig. 2B, statistical evaluations of the
collected data clearly indicated that the levels of this aspartyl
protease signiﬁcantly decreased in PBL from AD patients
with respect to HD (P < 0.0001). Results obtained in two rep-
resentative AD patients and in one HD are reported in Fig.
2C. A further control was represented by lymphocytes from
some patients with non-Alzheimer disease (NAP, see Section
2). Interestingly, no signiﬁcant diﬀerence was detected be-
tween cell samples from HD and NAP in the Cathepsin D
expression level (Fig. 2B) Moreover, qualitative analysis by
static cytometry showed that Cathepsin D staining was
mostly diﬀused in the cytoplasm of lymphocytes from HD
Fig. 2. Quantitative analysis of Cathepsin D. Distribution of median values of ﬂuorescence intensity histograms, as revealed by ﬂow cytometry,
found in HD and AD lymphocyte samples (A). Mean expression levels (±S.E.) of Cathepsin D in HD, AD and NAP are shown in (B). (*) Indicates
P < 0.0001. Results obtained from PBL of two diﬀerent representative AD patients (black and grey lines) and one HD (full grey histogram) are
shown (C). Numbers represent median values of ﬂuorescence intensity histograms. In panels (D) and (E) qualitative analysis by IVM depicting the
Cathepsin D distribution in PBL is shown. To note that Cathepsin D was mostly diﬀused in the cell cytoplasm in PBL from HD (D) while it appeared
as polarized positive ﬂuorescence in the apical region of PBL from AD patients (E).
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tributed as positive small spots in the apical regions of the
cell cytoplasm in lymphocytes from AD patients (Fig. 2E).
On the basis of these results, and taking into account the
hypothesized immune dysfunction in AD [29] as well as liter-
ature data indicating Cathepsin D as an apoptosis-inducing
factor [6], we analyzed the susceptibility of PBL, freshly iso-
lated from AD and HD, to CD95/Fas-mediated apoptosis.
To this purpose lymphocytes were activated with IL2/PHA
for 72 h (see Section 2) and then triggered by IgM anti-Fas
monoclonal antiboby (clone CH11) for 48 h. Results obtained
by biparametric ﬂow cytometry analysis after cell staining
with annexin V-FITC/PI failed to reveal any signiﬁcant diﬀer-
ence in terms of apoptotic susceptibility between HD (con-
trol: 7.7 ± 2.1%; anti-Fas: 37.5% ± 5.3) and AD subjects
(control: 8.1 ± 2.1%; anti-Fas: 36.4% ± 5.9).3.3. Increased expression of b-amyloid precursor protein in
platelets from AD patients
On the basis of (i) previously demonstrated b-secretase activ-
ity exerted by cathepsins [15] and (ii) their inﬂuence on the
cleavage of APP [47], studies speciﬁcally devoted to the analysis
of APP molecule were carried out in platelets [16] (and PBL, see
below) from AD patients and HD. Using a speciﬁc monoclonal
antibody [21], APP expression was ﬁrst analyzed in platelets
from AD patients and HD by quantitative ﬂow cytometry. Re-
sults obtained clearly indicated (i) a signiﬁcantly diﬀerent distri-
bution of detected values in platelets from HD and AD (Fig.
3A); and (ii) a signiﬁcant (P < 0.0001) increase of APP expres-
sion in AD samples with respect to control samples (Fig. 3B).
Representative results obtained in one HD and two diﬀerent
AD patients are reported in Fig. 3C. Importantly, also in this
case, no signiﬁcant diﬀerence was detected between NAP and
E. Straface et al. / FEBS Letters 579 (2005) 2759–2766 2763HD (Fig. 3B). Moreover, qualitative analyses carried out by
IVM clearly indicated that, with respect to HD (Fig. 3D), plate-
lets from AD patients displayed a marked redistribution of
APP molecule that appeared to be accumulated in the cell body
and could also be detected in the apical region of the platelet
cytoplasm (Fig. 3E). Cell morphology and intracellular distri-
bution of molecules are mainly instructed by cytoskeletal net-
work family molecules, essentially actin microﬁlaments [42].
Hence, speciﬁc analyses of actin ﬁlaments known to be involved
in platelet physiology [12] were carried out by IVM technique.
As previously suggested [5], platelets from HD were character-Fig. 3. APP analysis in platelets. Distribution of median values of ﬂuorescenc
AD platelet samples (A). Mean expression levels (±S.E.) of APP in HD, AD
from platelets of two diﬀerent representative AD patients (black and grey
represent median values of ﬂuorescence intensity histograms. In panel (D) a
platelets is shown. To note that, with respect to HD (D), in platelets from A
cytoplasm (E). In panel (F) and (G) intracellular distribution of actin mic
network forming a cortical boundary line was detected in platelets from ADized by a diﬀuse distribution of the actin ﬁlaments in the cell
cytoplasm (Fig. 3F). By contrast, we observed that the accumu-
lation of APP in platelets from AD patients reported above (see
Fig. 3B) was accompanied by a marked rearrangement of actin
ﬁlaments. In particular, a peculiar marginalization of actin net-
work forming a cortical boundary line was detected (Fig. 3G).
3.4. Increased expression of b-amyloid precursor protein in
lymphocytes from AD patients
A parallel evaluation of APP expression level was also con-
ducted, by ﬂow and static cytometry, in PBL. Quantitativee intensity histograms as revealed by ﬂow cytometry, found in HD and
and NAP are shown in (B). (*) indicates P < 0.0001. Results obtained
lines) and one HD (full grey histogram) are shown in (C). Numbers
nd (E) qualitative analysis by IVM depicting the APP distribution in
D patients, the APP molecule appeared to be accumulated in the cell
roﬁlaments in platelets is shown. A peculiar marginalization of actin
patients (G). Actin distribution in platelets from HD is shown in (F).
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of APP expression levels in lymphocytes from HD with respect
to AD, as demonstrated by values reported in Fig. 4A. In par-
ticular, Mann–Whitney statistical analyses clearly indicated
that a signiﬁcant increase in APP expression (P < 0.0001)
was detectable in lymphocytes from AD patients with respect
to HD (Fig. 4B). Results obtained from representative sub-
jects, one HD and two diﬀerent AD, are reported in Fig. 4C.
Interestingly, no signiﬁcant diﬀerences were detected in cell
samples obtained from patients with NAP with respect to
HD (Fig. 4B). Qualitative analysis by static cytometry failed
to reveal any signiﬁcant diﬀerence, both in APP and actin ﬁl-
ament distribution, in lymphocytes from AD patients with re-
spect to HD and NAP (not shown). Finally, in consideration
of the results obtained, speciﬁc statistical analyses were also
carried out to evaluate whether signiﬁcant correlations were
detectable in APP expression in platelets versus lymphocytes
in both groups analyzed here (HD and AD). Results obtained
by regression analyses clearly indicated a positive correlation
between platelets and lymphocytes either in HD (Fig. 4D,
P = 0.0581) or in AD patients (Fig. 4E, P = 0.0299). Notably,
however, APP expression values were signiﬁcantly higher in
AD patients with respect to HD (note diﬀerent values of y-axis
in Fig. 4D and E).Fig. 4. APP analysis in PBL. Distribution of median values of ﬂuorescence in
lymphocyte samples (A). Mean expression levels (±S.E.) of APP in HD, AD
from PBL of two diﬀerent representative AD patients (black and grey lines)
represent median values of ﬂuorescence intensity histograms. Regression anal
correlation either in HD (D, P = 0.581, r = 0.384) or AD (E, P = 0.299, r = 0
‘‘amount’’ of APP both in platelets and PBL in AD patients.4. Discussion
In the present work, we demonstrate that in AD patients oxi-
dative imbalance, previously hypothesized to play a pathoge-
netic role [14], is not restricted to the brain, but it can also be
recognized in the peripheral circulation. By using peripheral
plasma, PBL and platelets from AD patients we have in fact
found that diﬀerent signs of redox changes occurred, all converg-
ing towards an intertwined network of oxidative alterations,
which seems to represent a hallmark of the disease. Importantly,
lymphocytes were not involved in this redox imbalance.
Redox balance. The fact that plasma antioxidants were de-
creased in AD patients with respect to HD is in accord with
literature data obtained evaluating the levels of vitamins with
antioxidant activity in human plasma. In fact, with respect
to healthy subjects, signiﬁcantly lower levels of vitamin A,
E and carotenoids were found in AD patients [8,51]. Further-
more, literature data regarding increased lipid peroxidation
[44] and plasma levels of homocysteine, a sulphydryl-
containing amino acid, in patients at risk of developing AD
[30,44], seem also to support our results. Changes in homocys-
teine homeostasis were indeed considered as responsible for in-
creased ROS generation [24]. Thus, the decreased antioxidant
activity in the peripheral circulation reported here, and relatedtensity histograms as revealed by ﬂow cytometry, found in HD and AD
and NAP are shown in (B). (*) indicates P < 0.0001. Results obtained
and one HD (grey full histogram) are shown in (C). Numbers in (C)
yses of the APP accumulation in platelets and PBL indicated a positive
.418) samples. To note the diﬀerent values of y-axis indicating diﬀerent
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determinant in the occurrence of Alzheimer disease.
Cathepsin D and APP accumulation. On the basis of these
data, we have also investigated whether these changes could
be associated with other parameters of importance in the
maintenance of the redox balance in the peripheral blood,
e.g. Cystatin C plasma levels and Cathepsin D content in lym-
phocytes [19,35]. Cystatin C is an inhibitor of cathepsins that
co-localizes with b-amyloid peptide and it was found increased
in cultured neurons exposed to oxidative stress [35]. In the
same vein, Cathepsin D, a protease detectable in diﬀerent cell
types whose primary function is to degrade proteins by bulk
proteolysis in lysosomes, has been suggested to be involved
in AD pathogenesis [36]. In fact, there is increasing evidence
that disturbance of normal balance and extralysosomal locali-
zation of cathepsins (as the accumulation of Cathepsin D in
the senile plaques) contribute to neurodegeneration in AD
[11,34,36]. From the results reported herein it appears well evi-
dent that not only in the central nervous system [1], but also in
the PBL of AD patients, the Cathepsin D balance was altered.
In fact, expression levels of Cathepsin D were found decreased
in PBL from AD patients if compared to that found in HD.
Furthermore, this molecule seems also to undergo an extralys-
osomal re-distribution. On the basis of these quantitative and
qualitative analyses we could hypothesize that this protease
leaves the lymphocyte lysosomal compartments and it is re-
leased in the plasma. This hypothesis is reinforced from data
obtained with Cystatin C. Levels of this cathepsin-inhibitory
enzyme were in fact found increased in plasma from AD pa-
tients. This could represent a compensatory activity aimed at
counteracting increased presence of Cathepsin D. Finally, in
this scenario, according with literature data dealing with met-
abolic alterations detectable in AD patients [3,37], the in-
creased APP content detected in platelets and PBL from AD
patients could suggest that an altered b-secretase activity ex-
erted by cathepsins can result in an alteration in the cleavage
of amyloid precursor protein, with its consequent accumula-
tion. Hence, we can hypothesize a general mechanism of
APP accumulation in various cell types, including cells from
peripheral blood. The relationship between AD and APP pat-
tern changes was also reported by Di Luca and coworkers,
which hypothesized a pathogenic role for speciﬁc APP iso-
forms in periphery [17]. In this context, our data on APP seem
to signiﬁcantly extend previous studies on this argument [29],
reinforcing the idea that the APP metabolism is altered not
only in neuritic plaque, but also in the peripheral blood
[20,13]. Furthermore, taking into account the results obtained
by Basun et al. [4] suggesting a plasmatic decrease of APP in
AD patients, we cannot rule out the possibility that the
absorption of APP by the platelets could contribute to this
phenomenon. In fact, it has been reported that APP is not ex-
pressed in non-nucleated cells, i.e. in platelet [22].
Cytoskeleton. Recent data point to the cytoskeleton compo-
nents of platelets as an important target of ROS [10]. In partic-
ular, actin ﬁlament crosslinks, probably due to protein thiols
modiﬁcation, can occur, compromising platelet integrity and
functions. In fact, platelets from AD patients showed signs
of oxidative damage in terms of microﬁlament reorganization,
patching at the cell periphery and thickening of cortical actin
boundary lines with respect to platelets from HD. In turn, oxi-
dative alterations of the cytoskeleton thiol groups in platelets
can modify their function in terms of aggregation and motility.In fact, changes in actin microﬁlaments were previously de-
tected in AD platelets since 1995 [28] and, although unclear,
vascular risk factors and platelet dysfunction have been impli-
cated in AD-related processes [7,41,45].
In the same vein of previous studies performed since many
years on diﬀerent in vitro and ex vivo systems [9,14,17,44],
including studies on olfactory neurons [18] and blood cells
[25], the present report points to oxidative abnormalities
detectable in plasma, PBL and platelets from a homogeneous
group of patients as AD-speciﬁc. Furthermore, according with
previous works [40] and with results we obtained on NAP pa-
tients, redox changes depicted herein could identify subsets of
patients who are at increased risk of symptomatic AD.
Altogether, these results suggest that redox changes at the
periphery, mirroring changes in the central nervous system,
could have a potential role as diagnostic determinants as well
as progression markers of the disease. Furthermore, a pathoge-
netic role for the herein described peripheral redox alterations
can also be taken into account in future studies aimed at dis-
criminating aging-associated AD processes from physiological
changes associated with ‘‘successful aging’’ conditions.References
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